Pharma-FinalReview(Lec1)

Ion disturbances that may be caused by SABAs administration include :
A-Hyperkalemia , Hypermagnesemia
B-Hypokalemia , Hypomagnesemia
C-Hypernatermia , Hypokalemia
D-Hyperchloremia,Hypermagnesemia
Click the card to flip 👆
1 / 30
Terms in this set (30)
Ion disturbances that may be caused by SABAs administration include :
A-Hyperkalemia , Hypermagnesemia
B-Hypokalemia , Hypomagnesemia
C-Hypernatermia , Hypokalemia
D-Hyperchloremia,Hypermagnesemia
B : Hypokalemia , Hypomagnesemia
ADRs associated w/ SABAs include :
(1)TC
(2)Hyperglycemia
(3)Hypomagnesemia
(4)Hypokalemia
(5)B2-mediated Skeletal muscle tremors
SABAs provide bronchodilation for _________where as LABAs provide bronchodilation for at least ________.
4-6 h
12 h
Remain the long-term controlles of choice in asthma ?
ICS
Therapeutic action of ICSinclude :
A.Dec inflammatory cascade
B.Reversing mucosal edema
C.Dec permeability of capillaries
D.Inhibiting releases of LTs
E.All of the above
E.
ICS deposition on the oral and laryngeal mucosa can cause adverse effects such as ?
Oropharyngeal candidiasis
Hprseness
Alternative drugs of asthma indications ?
(1)pts who are poorly controlled by conventional therapy
(2)pts who experience adverse effects 2ry to corticosteroid tx
Management of OPC associated w/ ICP deposition in asthma pts , usually by ?
Miconazole oral gel
LTB4 action
eosinphil &neutrophil chemotactic agent
Cysteinyl LTs ;actions ?
LTC4, LTD4, LTE4
constrict bronchiolar smooth muscles
increase endothelial permeability. promote mucus secretion.
oral corticosteroidPrednisoneacute exacerbation of asthma or other COPDOral/IV CSZileuton MOA*5-lipoxygenase inhibitor* > prevent formation of both Cysteinyl-LTs & LTB4zafrilukast and montelukast MOACysteinyl-LT-1-R antagonistsRegarding the PKs of LTs modifiers,which of the following is true : A-They are administered orally B-They all undergo hepatic metabolism C-Zileuton is excreted in urine whereas Zafirulkast and Montelukast undergo biliary excretion D-Zafirulkast absp is impaired w/ food intake E-All of the aboveEWhich of the following is true about discontinuation of LTs modifiers : A-If liver enzymes elevated 2-4x the upper limit of normal B-If liver enzymes elevated 3-5x the upper limit of normal C-If liver enzymes elevated 2-3x the upper limit of normal D-If the pt experienced side effects such as headache and dyspepsiaBMast cell stabilizerCromolynIpratropium use in astham tx can be useful in ?1)pts who are unable to tolerate SABAs 2)pts w/ concomitant COPD 3)In ED, Ipratropium&SABA > *tx of acute asthma exacerbation*overdose of *theophylline* is associated w/ ?(1)Seziures (2)Fatal arrhythmias*Theophylline* therapeutic action ?Bronchodilator Anti-inflammatoryA recombinant DNA-derived monoclonal Ab that selectively *binds to human IgE* :OmalizumabRegarding *omalizumab* which of the following is true : A-used for tx of moderate-sever persistent asthma in pts who are poorly controlled w/ conventional therapy B-Its use is limited by high cost ,ROA and adverse effect profile C-Secondary malignancies have been reported in pts used it D-Can cause serious anaphylactic rxn , arthralgias ,fever and rash E-All of the aboveEOmalizumab is administered:SCFoundation of therapy for COPD :*Inhaled* bronchodilators : B2-adrenergic agonists Anticholinergic agents > *ipratropium & tiotroprium*Preferred 1st-line tx of COPDLABAs & tiotropiumMainstay tx in asthma ?ICSMainstay tx in COPD ?LAMAsRoflumilast MOAPDE4 inhibitor *reduce inflammation* by inc cAMP in lung cellsRoflumilast SEs include :Headache Nausea Vomiting DiarrheaRoflumilast indications?severe COPD associated w/ *chronic bronchitis* and a hx of exacerbations